Preparation, characterization and in vitro cytotoxicity evaluation of docetaxel nanoparticles against A549 cell line

authors:

avatar Mohammad Shokrzadeh , avatar Zavosh Zalzar , avatar pedram Ebrahimnejad , *

Koomesh: Vol.21, issue 2; 340-346
published online: May 02, 2019
article type: Research Article
received: February 07, 2018
accepted: November 02, 2018

how to cite: Shokrzadeh M, Zalzar Z, Ebrahimnejad P. Preparation, characterization and in vitro cytotoxicity evaluation of docetaxel nanoparticles against A549 cell line. koomesh. 2019;21(2):e153077. 

Abstract

Introduction: Docetaxel (DTX) is one of the most potent anticancer drugs in the taxane family. The commercial formulation of DTX for clinical use consists of high concentrations of tween80, which has been caused serious patient`s difficulties. Therefore, preparation of novel drug delivery system with ability of removing tween 80 and targeting on cancer tissue can lead more effective and also decrease side effects. This study is focused on preparation, characterization and cytotoxicity evaluation of docetaxel and poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs) against a tumor cell line. Materials and Methods: NPs of DTX and PLGA was prepared by a modified emulsification/solvent diffusion method. Then the obtained NPs were characterized and evaluated. For this purpose, 10000 viable cells were seeded in each well of 96-well plate and after 24 hours of incubation different concentrations of conventional and NPs were added to the wells. Then mitochondrial dehydrogenase activities in living cells were determined at 24, 48 and 72 hours by MTT assay. Results: The average diameter of the NPs was approximately 184.3 ± 14.6 nm with poly dispersity index of 0.15. Notably, the results showed significant increase in cytotoxicity of the NPs against the A549 cell line. Inhibitory concentration (IC50) of free drug and NPs was 20.66 ± 0.22, 18.27 ± 0.45, 10.64 ± 0.38 and 0.57 ± 0.04, 0.16 ± 0.04, 0.07 ± 0.01 (µg/ml) at 24, 48 and 72 hours respectively. Conclusion: This study demonstrates the higher cytotoxicity of DTX-PLGA NPs on human lung cancer cell line. The present formulation can be considered for the further studies on other cell lines and in vivo evaluation.  

References

  • 1.

    Esmaeili F, Dinarvand R, Ghahremani MH, Ostad SN, Esmaily H, Atyabi F. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly (lactide-co-glycolide) nanoparticles. Anticancer Drugs 2010; 21: 43-52.

  • 2.

    Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002; 94: 1457-1465.

  • 3.

    Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.

  • 4.

    Bowerman CJ, Byrne JD, Chu KS, Schorzman AN, Keeler AW, Sherwood CA, et al. Docetaxel-loaded PLGA nanoparticles improve efficacy in taxane-resistant triple-negative breast cancer. Nano Lett 2017; 17: 242-248.

  • 5.

    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.

  • 6.

    Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, Stovall M, et al. Second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 2011; 12: 353-360.

  • 7.

    Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel: a review. Anticancer Drugs 2007; 18: 95-103.

  • 8.

    Zhang W, Shi Y, Chen Y, Ye J, Sha X, Fang X. Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors. Biomaterials 2010; 32: 2894-2906.

  • 9.

    Baker J, Ajani J, Scott F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009; 13: 49-59.

  • 10.

    Mohammadi M, Dinarvand R, Esfandiadri F, Ebrahimnejad P. Encapsulation of irinotecan in polymeric nanoparticles: Characterization, release kinetic and cytotoxicity evaluation. Nanomedicine J 2016; 3: 159-168. (Persian).

  • 11.

    Fakhavar Z, Ebrahimnejad P, Akbarzadeh A. Nanoliposomes: Synthesis methods and applications in cosmetics. J Cosmet Laser Ther 2015; 12: 1-31.

  • 12.

    Jafari M, Heidari D and Ebrahimnejad P. Synthesizing and characterizing functionalized short multiwall carbon nanotubes with folate, magnetite and polyethylene glycol as multi-targeted nanocarrier of anti-cancer drugs. IJPR 2016; 15: 449-456. (Persian).

  • 13.

    Enayati AA, Ebrahimnejad P. Nano pesticides, production and application, a review. J Mazandaran Univ Med Sci 2012; 22: 298-311. (Persian).

  • 14.

    Ebrahimnejad P, Mir M. Preparation and characterization of bifunctional nanoparticles of vitamin E TPGS-emulsified PLGA-PEG-FOL containing deferasirox. Nanosci Nanotechnol Asia 2014; 4: 80-85. (Persian).

  • 15.

    Akhtari J, Ebrahimnejad P, Rafiei. A review on the use of nanoparticles in the release of growth factors. J Mazandaran Univ Med Sci 2015; 24: 431-445. (Persian).

  • 16.

    Bouissou C, Rouse JJ, Price R, Van Der Walle CF. The influence of surfactant on PLGA microsphere glass transition and water sorption: Remodeling the surface morphology to attenuate the burst release. Pharm Res 2006; 23: 1295-1305.

  • 17.

    Esmaeili F, Dinarvand R, Ghahremani MH, Amini M, Rouhani H, Sepehri N, et al. Docetaxel albumin conjugates: preparation, in vitro evaluation and biodistribution studies. J Pharm Sci 2008; 98: 2718-2730.

  • 18.

    Esmaeili F1, Ghahremani MH, Ostad SN, Atyabi F, Seyedabadi M, Malekshahi MR, et al. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target 2008; 16: 415-423.

  • 19.

    Niapour N, shokri gara geshlagi S, amani M, sharifi pasandi M, salehi H, niapour A. Effects of all trans retinoic acid on apoptosis induction and notch1, hes1 genes expression in gastric cancer cell line MKN-45. Koomesh 2016; 17: 1024-1032. (Persian).

  • 20.

    Eskandari A, Jaberipour M, khodadadi A, Ghaderi A. IL-23 and IL-27 gene expression in three breast cancer cell lines and metastatic and non-metastatic lymph nodes in breast cancer patients. Koomesh 2011; 12: 428-434. (Persian).##[21 Shokrzadeh M, Azadbakht M, Ahangar N, Naderi H, Saeedi Saravi SS. Comparison of the cytotoxic effects of Juniperus sabina and Zataria multiflora extracts with Taxus baccata extract and Cisplatin on normal and cancer cell lines. Pharmacogn Mag 2010; 6: 176-179.

  • 21.

    Shokrzadeh M, Habibi E, Dadkhah G, Modanloo M. Evaluating the cytotoxicity effect of hydroalcoholic extract of juglans regia on human cancer cell lines (HepG2- HeLa) by MTT Assay. J Mazandaran Univ Med Sci 2016; 26: 160-164. (Persian).

  • 22.

    Mehdizadeh M, Rouhani H, Sepehri N, Varshochian R, Ghahremani MH, Amini M, et al. Biotin decorated PLGA nanoparticles containing SN-38 designed for cancer therapy. Artif Cells Nanomed Biotechnol 2017; 45: 495-504.

  • 23.

    Balzus B, Sahle FF, Hnzke S, Gerecke C, Schumacher F, Hedtrich S, et al. Formulation and ex vivo evaluation of polymeric nanoparticles for controlled delivery of corticosteroids to the skin and the corneal epithelium. Eur J Pharm Biopharm 2017; 115: 122-130.

  • 24.

    Ebrahimnejad P, Dinarvand R, Sajadi A, Jaafari MR, Nomani AR, Azizi E. Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines. Nanomedicine 2010; 6: 478-486.

  • 25.

    Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis Advanced drug delivery reviews. Adv Drug Deliv Rev 2002; 54: 631-651.

  • 26.

    Davda J, Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 2002; 233: 51-59.

  • 27.

    Fu K, Pack DW, Klibanov AM, Langer R. Visual evidence of acidic environment within degrading poly (lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res 2000; 17: 100-106.

  • 28.

    Lin HL, Liu TY, Chau GY, Lui WY, Chi CW. Comparison of 2- methoxyestradiolinduced, docetaxel induced, and paclitaxelinduced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 2000; 89: 983-994.

  • 29.

    Rafiei P, Haddadi A. Docetaxel-loaded Plga and Plga-Peg nanoparticles for intravenous application: pharmacokinetics and biodistribution profile. Int J Nanomedicine 2017; 12: 935-939.

  • 30.

    Wenzel C, Locker GJ, Schmidinger M, Rudas M, Taucher S, Gnant MFX, et al. Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+ granulocyte colony stimulating factor. Anticancer Drugs 2002; 13: 67-74.

  • 31.

    Yutao L, Kai L, Jie P, Bin L, Si-Shen F. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials 2010; 31: 330-338.

  • 32.

    Ho-Young H, In-San K, Ick CK, Yong-Hee K. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Controlled Release 2008; 128: 23-33.

  • 33.

    Mei L, Zhang Y, Zheng Y, Tian G, Song C, Yang D, et al. A novel docetaxel-loaded poly (-Caprolactone)/pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatment. Nanoscale Res Lett 2009; 4: 1530-1539.

  • 34.

    Shokrzadeh M, Ebrahimnejad P, Omidi M, Shadboorestan A, Zaalzar Z. Cytotoxity evaluation of docetaxel nanoparticles by culturing HepG2 carcinoma cell lines. J Mazandaran Univ Med Sci 2012; 22: 2-10. (Persian).

  • 35.

    Feng SS, Mu L, Win KY, Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem 2004; 11: 413-424.

  • 36.

    Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 2002; 83: 273-286.

  • 37.

    Jin C, Bai L, Wu H, Song W, Guo G, Dou K. Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells. Pharm Res 2009; 26: 1776-1784##.